Paul, Weiss is representing Merck in its all-cash $10.8 billion acquisition of Prometheus Biosciences, Inc. Merck will acquire the company for $200 per share under the deal, and expected to close in the third quarter of 2023, pending regulatory approvals and other conditions.
Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.
The Paul, Weiss team is led by Laura Turano, Scott Barshay and Jennifer Wang, and includes corporate partner Christodoulos Kaoutzanis; intellectual property partner Jonathan Ashtor and counsel Bonnie Chen; executive compensation partner Jarrett Hoffman; real estate partner Peter Fisch; tax counsel Alyssa Wolpin; and environmental counsel William O’Brien.
About Paul, Weiss, Rifkind, Wharton & Garrison
Paul, Weiss, Rifkind, Wharton & Garrison LLP is a firm of about 1,000 lawyers with diverse backgrounds, personalities, ideas and interests who provide innovative and effective solutions to our clients’ most complex legal and business challenges. The firm represents many of the world’s largest and most important public and private corporations, asset managers and financial institutions, and clients in need of pro bono assistance.
